•Journal•ISSN: 1533-3175
American Journal of Alzheimers Disease and Other Dementias
SAGE Publishing
About: American Journal of Alzheimers Disease and Other Dementias is an academic journal published by SAGE Publishing. The journal publishes majorly in the area(s): Dementia & Cognition. It has an ISSN identifier of 1533-3175. It is also open access. Over the lifetime, 1762 publications have been published receiving 42935 citations. The journal is also known as: American journal of Alzheimer's disease and other dementias & AJADD.
Topics: Dementia, Cognition, Population, Family caregivers, Cognitive decline
Papers published on a yearly basis
Papers
More filters
TL;DR: In this paper, the authors present a view of the behaviors exhibited by individuals with dementia, including wandering, vocalizations and aggression, and provide a conceptual framework to guide further research and clinical practice.
Abstract: Thedisruptive behavior ofpersonswithdementia isa problem ofconsiderable clinical interest andgrowing scientific concern.This paperoffers a viewofthese behaviors asexpres- sions ofunmetneeds orgoals andprovides a comprehensive conceptual framework toguide further research andclinical practice. Empiricalfindings andclinical impressions related to wandering, vocalizations andaggression tosupport andillus- tratetheframework arepresented. Introduction Disruptive behaviors displayed bydemented elderly often result innursing homeplacement' andchallenge theskills of even thebest-trained nursing personnel. Despite increasing attention fromresearchers tobehaviors suchas wandering, vocalizations andaggression, efforts toexplain these phenom-
561 citations
TL;DR: The amyloid cascade model is introduced, the main neuropathological hallmarks are discussed, and emerging biomarkers from cerebrospinal fluid assays, magnetic resonance imaging, nuclear medicine, and electrophysiology are discussed.
Abstract: This comprehensive, pedagogically-oriented review is aimed at a heterogeneous audience representative of the allied disciplines involved in research and patient care. After a foreword on epidemiology, genetics, and risk factors, the amyloid cascade model is introduced and the main neuropathological hallmarks are discussed. The progression of memory, language, visual processing, executive, attentional, and praxis deficits, and of behavioral symptoms is presented. After a summary on neuropsychological assessment, emerging biomarkers from cerebrospinal fluid assays, magnetic resonance imaging, nuclear medicine, and electrophysiology are discussed. Existing treatments are briefly reviewed, followed by an introduction to emerging disease-modifying therapies such as secretase modulators, inhibitors of Abeta aggregation, immunotherapy, inhibitors of tau protein phosphorylation, and delivery of nerve growth factor.
276 citations
TL;DR: There appears to be a resistance of the psychiatric symptoms associated with dementia to respond to prescribed psychotropic medications.
Abstract: In a survey of drug prescribing, we interviewed 41 dementia patients and 37 normal elderly, both groups living in their homes. We found that 83 percent of the dementia patients and more than half (54 percent) of the normal elderly were receiving medications. The use of psychotropic medications was mainly limited to the dementia group, who continued to show psychopathology as measured by the BPRS (Brief Psychiatric Rating Scale) in spite of pharmacotherapy. The degree of dementia measured by Mini-Mental State examination1 was significantly correlated with the degree of psychopathology measured by Brief Psychiatric Rating Scale (BPRS).2 Polypharmacy (use of multiple psychotropic drugs) was not a problem in our sample. There appears to be a resistance of the psychiatric symptoms associated with dementia to respond to prescribed psychotropic medications.
266 citations
TL;DR: It is suggested that AD and FTLD are anatomically distinct, with degeneration of a posterior parietal network in AD and degenerations of a paralimbic fronto-insular-striatal network in FTLD.
Abstract: To better define the anatomic distinctions between Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD), we retrospectively applied voxel-based morphometry to the earliest magnetic resonance imaging scans of autopsy-proven AD (N = 11), FTLD (N = 18), and controls (N = 40). Compared with controls, AD patients showed gray matter reductions in posterior temporoparietal and occipital cortex; FTLD patients showed atrophy in medial prefrontal and medial temporal cortex, insula, hippocampus, and amygdala; and patients with both disorders showed atrophy in dorsolateral and orbital prefrontal cortex and lateral temporal cortex (P(FWE-corr) < .05). Compared with FTLD, AD patients had decreased gray matter in posterior parietal and occipital cortex, whereas FTLD patients had selective atrophy in anterior cingulate, frontal insula, subcallosal gyrus, and striatum (P < .001, uncorrected). These findings suggest that AD and FTLD are anatomically distinct, with degeneration of a posterior parietal network in AD and degeneration of a paralimbic fronto-insular-striatal network in FTLD.
261 citations
TL;DR: The present study confirms the MMSE score 23/24 as a valid cutoff level for the diagnosis of dementia in Greece.
Abstract: Aim of the study: To validate the MMSE in Greece.Materials and Methods: 151 subjects took part in the study—64 non-demented subjects (42 males and 22 females) and 87 demented patients (44 males and...
237 citations